Page last updated: 2024-09-05

sb 203580 and Nanaomycin

sb 203580 has been researched along with Nanaomycin in 1 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(Nanaomycin)
Trials
(Nanaomycin)
Recent Studies (post-2010) (Nanaomycin)
3,48941,137500

Protein Interaction Comparison

ProteinTaxonomysb 203580 (IC50)Nanaomycin (IC50)
Chain A, RNA-directed RNA polymerase NS5Dengue virus 2 16681-PDK535.04
rac GTPase-activating protein 1 isoform aHomo sapiens (human)76.42
VifHuman immunodeficiency virus 14.16
TatHuman immunodeficiency virus 1100
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)4.16
putative polyprotein3.824

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Clutter, MR; Crane, JM; Krutzik, PO; Nolan, GP1

Other Studies

1 other study(ies) available for sb 203580 and Nanaomycin

ArticleYear
High-content single-cell drug screening with phosphospecific flow cytometry.
    Nature chemical biology, 2008, Volume: 4, Issue:2

    Topics: Animals; Cell Line, Tumor; Drug Evaluation, Preclinical; Flow Cytometry; Humans; Janus Kinases; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinases; Phosphorus; Sensitivity and Specificity; Signal Transduction; STAT Transcription Factors

2008